glp-1 drugs pharmaceutical companies partnerships 2025 GLP-1 Analogues Market Report, Growth and Forecast How Lilly Reached $1 Trillion:

NPY and PYY A part of the pancreatic polypeptide family, NPY is a 36-amino acid peptide

The key is designing the cost-share to discourage casual use while keeping the medication affordable for employees who are clinically committed to treatment

This dual mechanism makes it particularly effective for patients whose weight gain is driven by emotional eating, food cravings, or the "reward" component of overeating

The 'Switch' is On: Proving the Viability of Oral Maintenance Therapy The ATTAIN-MAINTAIN study was a first-of-its-kind Phase 3 trial designed to answer a critical clinical question: can patients who have successfully lost weight on injectable GLP-1s (Wegovy or Zepbound) switch directly to an oral agent and maintain their results

Other GLP-1 drugs are completing trials for MASH and may be approved for it soon